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Abstract
Background: Using planar gamma scintigraphy of inhaled radioaerosols, we have developed new analytical
methods for assessing homogeneity of aerosol deposition and time-dependent particle clearance on a pixel-by-
pixel basis, and applied them to a therapeutic cystic fibrosis (CF) study.
Methods: At baseline and 1 month after beginning treatment with ivacaftor, a cystic fibrosis transmembrane
regulator modulator for CF patients with at least one copy of the G551D mutation (n¼ 13), initial deposition
and subsequent mucociliary clearance (MCC) of radiolabeled particles (99mTechnetium-sulfur colloid, 5 lm
mass median aerodynamic diameter) inhaled under controlled breathing conditions were measured.
Results: Improved homogeneity of deposition, that is, decreased areas of higher and lower particle deposition in
the lungs, was observed following ivacaftor treatment. The mean number ratio (NR) of pixels with higher
deposition, relative to lung size, decreased from 0.14 to 0.09 ( p¼ 0.003) and mean NR of colder pixels decreased
from 0.23 to 0.19 ( p¼ 0.004). Particle clearance was also improved following treatment, with mean MCC
through 60 minutes equal to 12% versus 24%, without and with treatment, respectively ( p¼ 0.010). Pixel-level
analysis of MCC showed that (1) the fraction of pixels clearing >30% at 60 minutes was increased from 0.13 to
0.32 ( p¼ 0.007); and (2) the fraction of pixels clearing <5% at 60 minutes was decreased from 0.54 to 0.37
( p¼ 0.014), indicating an overall recruitment of more fast-clearing lung regions with ivacaftor treatment.
Conclusion: These detailed pixel analyses of deposition and clearance homogeneity may supplement traditional
methods that use large regions of interest for assessing efficacy and mechanisms of therapeutic intervention in
patients with airways disease.
Keywords: gamma scintigraphy, mucociliary clearance, particle deposition
Introduction
The homogeneity of particle deposition and muco-ciliary clearance (MCC) measured by gamma scin-
tigraphy has generally been assessed by partitioning lung
images into multiple, but relatively large, regions of interest
(ROIs).(1,2) We recently showed, however, that pixel anal-
ysis was more sensitive for the detection of differences in
particle deposition heterogeneity between mild, adult cystic
fibrosis (CF) patients and healthy adults than simple ROI
assessments of central versus peripheral (C/P) deposition.(3)
More specifically, the number of ‘‘cold’’ pixels in the whole
lung, that is, those with less than expected deposition rel-
ative to pixel volume, was significantly greater in mild CF
versus healthy subjects. These low deposition zones oc-
curred primarily in the apical lung region and increased with
decreasing lung function.
We hypothesized that (1) analyses at the pixel level can
also be used to assess the homogeneity of particle clearance
over time, that is, a measure of MCC homogeneity and (2)
these methods may then be applied to the assessment of new
therapies designed to improve MCC and lung function in CF.
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We recently participated in a multisite study to assess
the clinical and physiological effects of ivacaftor (Vertex
Pharmaceuticals) in patients with at least one copy of the
G551D mutation in their cystic fibrosis transmembrane
regulator (CFTR) gene.(4) Ivacaftor was recently approved
as a CFTR potentiator for CF patients aged 6 and above with
gating mutations, including the G551D mutation. At the four
participating sites, MCC from the whole lung was measured
using standardized methods(5) at baseline and two time
points (1 and 3 months) after beginning orally administered
ivacaftor. Results showed that MCC was significantly im-
proved following both 1- and 3-month treatment compared
to predrug.(4) Lung function endpoints were also improved
dramatically across all sites. Forced expiratory volume in 1
second (FEV1) had a mean 6.7% absolute change after 1-
month ivacaftor treatment,(4) which was maintained through
6 months of treatment.
Given the clear improvement in both lung function and
MCC associated with ivacaftor treatment, we applied a new
method for pixel analyses of deposition and clearance homo-
geneity to (1) assess relationships between ivacaftor-induced
changes in particle deposition and clearance homogeneity, and
lung function in these patients and (2) compare pixel analyses
with the more traditional ROI-dependent measures in the same
data set. While the deposition methodology has been described
previously,(3) the new method for pixel-level analysis of
clearance was developed as part of this effort and is described in
this study. Only data from the University of North Carolina
(UNC) and Johns Hopkins University (JHU) sites were chosen
for these analyses, as only these two sites used the 241Amer-
icium (241Am) fiducial markers to allow accurate alignment of
images (described further in Methods).
Methods
Subjects
Analyzed data came from subjects who had participated
in the previously published observational study of ivacaftor
in patients with G551D-CFTR.(4) Only data from two of the
four study sites were analyzed, as these sites utilized ex-
ternal 241Am fiducial markers, which allowed accurate im-
age alignment needed for these analyses. A total of 13 CF
patients, seven (age range 22–36 years; mean age 25.5 years;
three females; mean FEV1 53.0 – 16.8% predicted) from the
UNC at Chapel Hill, NC, and six subjects (age range 14–39
years; mean age 25.0 years; two females; mean FEV1
77.5 – 28.2% predicted) from JHU in Baltimore, MD. Particle
deposition and MCC measurements, using 2D gamma scin-
tigraphy images, were performed at baseline before initiation
of ivacaftor therapy and again 1 month after starting therapy.
The study was approved by UNC and JHU institutional re-
view boards. Participants, or their guardians, provided written
informed consent.
Radiolabeled aerosol inhalation
Aerosol particle deposition and MCC were visualized by
gamma scintigraphy after inhaling a sulfur colloid (SC)
aerosol labeled with 99mTechnetium (99mTc). Briefly, SC
particles radiolabeled with technetium (99mTc-SC) were
prepared from sulfur colloid kits (CIS-Sulfur Colloid; CIS-
US, Inc., Bedford, MA) by either the hospital nuclear
pharmacy or Cardinal Health following the procedure
provided by the manufacturer. The submicrometer [0.22 lm,
geometric standard deviation (SD) = 1.75] 99mTc-SC parti-
cles are insoluble and were suspended in normal saline so-
lution for delivery by the Devilbiss 646 jet nebulizer and
compressor (Devilbiss 646; Sunrise Medical, Somerset, PA).
The aerosol (5 lm mass median aerodynamic diameter) was
inhaled under controlled breathing conditions (30 breaths/min
at 500 mL/s), while the subject was seated with his/her back
against a gamma camera or single scintillating crystal until
approximately 40 lCi was deposited in the respiratory tract.
Immediately following inhalation, within approximately 5
minutes, the subject was seated at the gamma camera for 2D
imaging.
Gamma scintigraphy
The gamma scintigraphy procedures consisted of a sin-
gle transmission scan of the thorax using a planar 57Cobalt
source, a dynamic emission scan of 99mTc-SC over 64
minutes, and a single emission scan of residual 99mTc-SC
activity remaining in the lungs approximately 20 hours la-
ter. Large field-of-view, 2D gamma cameras used at UNC
and JHU were an Orbiter (Mie America, Chicago, IL) and
a Siemens Orbiter (Scintillation Technologies, Inc., Balti-
more, MD), respectively. Images were collected in a
128 · 128 matrix resulting in a pixel size of 3.19 mm at the
UNC site and 3.48 mm at the JHU site. Deposition and MCC
were measured only from the right lung to avoid the con-
founding effects of stomach activity on the left lung. Image
analysis was performed with Image J [ver. 1.45s; National
Institutes of Health (NIH)].
To assist image alignment during analysis, two small
(2 mm diameter), low energy (<1 lCi) 241Am markers were
placed on the subject’s back as fiducial markers (Fig. 1).
These markers were centered along the spine at the C7
spinous process and an appropriate, fixed distance caudad
(typically approximating the L2 spinous process). Figure 1c
shows that the 2 mm 241Am sources were associated with a
width of 6 mm (or 2 pixel width) at half maximum. In other
words, we had sufficient resolution to distinguish two 2 mm
sources that are separated by 6 mm. While the image of
these markers is clearly not confined to a single pixel, there
is peak activity associated with one pixel that allows us to
align the images to a reasonable degree.
The transmission scan of the thorax (Fig. 2a) was acquired
to define the right lung outline, defined as an isocontour
boundary set at approximately 3X the abdominal background,
and to simulate homogenous deposition of particles. Pixel
brightness on the transmission scan reflects areas of higher
scintigram counts and is generally proportional to lung thick-
ness. The acquisition continued until approximately 50K counts
were accumulated in the right lung ROI.
The pixel counts in the right lung were smoothed with a
Gaussian filter and normalized to the median counts per
pixel.(3) The Gaussian smoothing (low-pass filter) is a typ-
ical image conditioning routine to eliminate artifacts caused
by large random variations in binning counts, particularly
those seen in images with low average counts. Gaussian
smoothing is regarded as the best noise filter that maintains
edge definition of larger areas. We used the plug-in routine
available with the ImageJ 1.45s image reader (available
from the public domain at the NIH) with a small radius of
two pixels to minimize reduction in resolution.
The first 2-minute image after radiolabel inhalation
served as the initial particle deposition image (Fig. 1a),
which was background and decay corrected, and Gaussian
smoothed and normalized to median counts in the right lung
(Fig. 2b). Separately, a 4-minute initial period of imaging
after radiolabel inhalation and a 4-minute period 60 minutes
later were used to calculate cumulative MCC values in in-
dividual pixels. Brighter pixels in Figure 2b represent areas
of higher particle deposition. All images were aligned,
background subtracted, Gaussian smoothed, decay cor-
rected, and normalized to mean counts in the right lung.
Deposition homogeneity
Homogeneity of particle deposition was determined by a
method described previously.(3) In brief, the normalized,
initial deposition images were divided by the normalized
transmission image. A deposition:transmission ratio of 1
would indicate the expected amount of particle deposition
for the volume of lung (as indicated by the transmission scan
intensity) captured in a given pixel on these 2D images. The
rationale for defining the deposition:transmission thresholds
associated with ‘‘hot’’ and ‘‘cold’’ pixels is described in
detail in our previous publication.(3)
Pixels with a deposition/transmission ratio >2 (Fig. 2c)
were designated as ‘‘hot’’ pixels, meaning they contained a
higher than expected level of particle deposition. Pixel ratios
of <0.5 (Fig. 2d) were designated as pixels with lower than
expected deposition or ‘‘cold’’ pixels. All other pixels were
considered to be areas of normal deposition (i.e., propor-
tional to pixel volume). The fraction of the right lung area
that comprised either hot or cold pixels was measured to
determine the hot and cold number ratios (NRs). The frac-
tion of total counts contained within hot pixels was calcu-
lated and termed the sum ratio (SR) of hot pixels.
Other regional deposition metrics: C/P and skew
The hot and cold deposition metrics described above were
compared to the more traditional measures of the normal-
ized central to peripheral ratio (nC/P) of deposition and the
skew of the histogram distribution (counts/pixel vs. number
of pixels) in the whole right lung.(3,6)
To assess C/P deposition, two ROIs were created over the
right transmission lung image (Fig. 2a): (1) the same outline
region created for the whole lung as described previously,
and (2) a central (C) rectangular ROI, created by first cir-
cumscribing a rectangular whole lung region on the edges of
the whole lung outline region and then creating a C region
FIG. 2. (a) Co57 transmission scan of the thorax was
acquired to define the lung outline and simulate a homog-
enous deposition of particles. The pixel counts in the right
lung were normalized to median counts in the right lung.
(b) Particle deposition image. The pixel counts in the right
lung were normalized to median counts in the right lung. (c)
Hot regions of deposition. Normalized deposition image
(Fig. 1b) was divided by the normalized transmission image
(Fig. 1a) with the resulting ratio of pixel value >2 designated
as ‘‘hot’’ pixels of higher than expected deposition. (d) Cold
regions of deposition. Pixel ratios <0.5 were designated as
pixels with lower than expected deposition or ‘‘cold’’ pixels.
FIG. 1. (a) Sample initial deposition image for 99mTc-SC
(t = 0) with 241Am markers on upper and lower back. (b)
Sample image at t = 60 minutes with 241Am markers. (c)
Histogram of 241Am activity for horizontal cross-sectional
line through the center of upper 241Am marker in (a). Width
at half-max was 6 mm or about two pixels with our camera
resolution. 241Am, 241Americium; 99mTc, 99mTechnetium;
SC, sulfur colloid.
with dimensions equal to half the whole lung rectangular
ROI’s width and one-half its height. The C region was po-
sitioned on the medial boundary of the lung, centered by
height. The peripheral (P) region was defined as the area
lying between the rectangular central and whole lung outline
ROI. These regions were overlaid onto the initial aerosol
deposition scans to determine the initial counts in each re-
gion. We then calculated the ratio of central-to-peripheral
counts (C/P) and deposition, and normalized this ratio by
dividing by the central-to-peripheral ratio for the transmis-
sion scan to obtain nC/P.(3,6)
To determine skew of the deposition, frequency distri-
bution histograms were constructed from the right lung
deposition images and the whole lung outline ROI created
from the transmission scan, with the number of pixels with a
given count value (expressed as a fraction of total pixels) on
the y axis and the count values on the x-axis.(7) These his-
tograms were analyzed for skew (a measure of histogram
symmetry, the third moment about the mean of the histo-
gram),(7) with decreasing skew reflecting increased deposi-
tion homogeneity.
MCC homogeneity
The scintigrams (sum of 2 two-minute images) obtained
60 minutes postdeposition were decay and background
corrected and aligned with the initial deposition images
(Fig. 3a) using the 241Am fiducial markers (Fig. 1). The
retained radioactive counts in each pixel after 60 minutes
(Fig. 3b for 60 minutes) were divided by those of the initial
deposition image (Fig. 3a) to obtain a map of MCC (i.e., 1—
pixel retention fraction at 60 minutes) values from 0 to 1
(Fig. 3c for 60 minutes). Because signal-to-noise ratios are
extremely low in pixels with negligible initial particle de-
position, the cold pixels from the deposition heterogeneity
maps defined in Figure 2d were subtracted from the clear-
ance image to remove artifacts (Fig. 3c). The brighter areas
in Figure 3c correspond to areas of greater clearance.
To identify and quantitate fast clearing pixels, we defined
fast clearing pixels as those that had >2.5 times the mean
pretreatment right lung clearance value at 60 minutes. The
fast clearing ratio (FR) was determined as the fraction
of fast clearing pixels relative to total right lung pixels.
Similarly, we defined slow clearing pixels as those that
were 2.5 times less than the mean pretreatment right lung
clearance value at 60 minutes, and the slow clearing ratio
(SLR) as the fraction of slow cleared pixels relative to total
lung pixels.
Statistical analyses
Stata for Macintosh was used for statistical analyses.
Comparison between pretreatment and posttreatment vari-
ables were made by Wilcoxon matched paired signed-rank
test. Group comparisons between sites (i.e., UNC vs. JHU)
were made by two-sample Wilcoxon rank-sum test. The
significance of relationships between individual variables
was tested using linear regression analysis.
Results
Deposition homogeneity
The pretreatment and posttreatment results for individual
and combined sites are given in Table 1. As reported in the
larger clinical trial,(4) patients had a significant improvement
in lung function following 1-month treatment with ivacaftor.
There was a trend for patients at UNC to have lower pre-
treatment lung function (FEV1 percent of predicted) than
those at JHU ( p = 0.12). There was a significant reduction in
cold pixel NR following initiation of ivacaftor therapy,
suggesting a reduction in poorly ventilated lung regions and,
thereby, improved access for aerosol delivery.
Figure 4a illustrates the individual subject changes in NR
of cold deposition pixels, coded by site ( p = 0.001 for pre-
treatment vs. posttreatment). The NR of cold pixels was also
highly correlated with FEV1 percent of predicted (r = -0.79,
p < 0.01, Fig. 4b). There were also site differences (Table 1)
in cold pixel NR and hot pixel SR that were consistent with
the trend toward lower lung function in patients at UNC
(Table 1 and Fig. 4b).
We also observed a significant reduction in NR and SR of
hot pixels following therapy ( p = 0.005 and 0.007, respec-
tively for pretreatment vs. posttreatment), but no change in
either C/P or skew. Figure 4c illustrates the individual
subject changes in NR of hot spots, coded by site. As with
the cold pixels, both NR and SR of hot pixels were also
highly correlated with FEV1 percent of predicted (r = -0.73
and r = -0.75, respectively, p < 0.01). However, despite
these significant relationships between baseline lung func-
tion and deposition homogeneity, the changes in either cold
FIG. 3. (a) An initial deposition image. (b) Background- and decay-corrected 60-
minute image. (c) The retained particles in each pixel after 60 minutes (b for 60
minutes) divided by those of the initial deposition image (a) to obtain a map of
clearance (i.e., 1—pixel retention fraction at 60 minutes) values ranging from 0 to 1.
The brighter areas correspond to areas of greater clearance.
Table 1. Lung Function and Deposition Homogeneity by Site and for All Subjects
UNC pre (n = 7) UNC post JHU pre (n = 6) JHU post All pre (n = 13) All post
FEV1 percent of predicted 53 (17) 72 (22) 77 (28) 86 (27) 64 (25) 78* (24)
NR cold 0.28 (0.07) 0.24 (0.09) 0.18^ (0.09) 0.13^ (0.07) 0.23 (0.09) 0.19* (0.10)
NR hot 0.19 (0.08) 0.12 (0.09) 0.09 (0.11) 0.05 (0.06) 0.14 (0.10) 0.09* (0.08)
SR hot 0.45 (0.18) 0.29 (0.20) 0.19^ (0.22) 0.11^ (0.12) 0.33 (0.24) 0.21* (0.19)
nC/P 1.68 (0.25) 1.70 (0.39) 1.55 (0.21) 1.64 (0.15) 1.62 (0.23) 1.68 (0.29)
Skew 1.56 (0.45) 1.39 (0.46) 1.08 (0.55) 1.12 (0.41) 1.34 (0.54) 1.27 (0.44)
Mean (SD) values displayed in table.
*p < 0.01 compared to Pre.
^p < 0.05 for UNC versus JHU.
FEV1, forced expiratory volume in 1 second; JHU, Johns Hopkins University; nC/P, normalized central to peripheral ratio; NR, number
ratio; SD, standard deviation; SR, sum ratio; UNC, University of North Carolina.
FIG. 4. (a) Number of ‘‘cold’’ pixels normalized to lung area (NR) before
and after 1 month of ivacaftor therapy ( p = 0.001 for pretreatment vs.
posttreatment). Solid lines are from subjects recruited by UNC and dashed
lines from JHU. (b) Number of ‘‘cold’’ pixels normalized to lung area (NR
cold) versus FEV1 percent of predicted before and after 1 month of iva-
caftor therapy. r = -0.79 for all, p < 0.01, slope of linear regression = -0.003/
% FEV1. (c) Number of ‘‘hot’’ pixels normalized to lung area (NR hot)
before and after 1 month of ivacaftor therapy ( p = 0.005 for pretreatment vs.
posttreatment). Solid lines are from subjects recruited by UNC and dashed
lines from JHU. FEV1, forced expiratory volume in 1 second; JHU, Johns
Hopkins University; NR, number ratio; UNC, University of North Carolina.
or hot pixel indices (NR, SR) with treatment were not sig-
nificantly correlated with either baseline or changes (i.e.,
posttreatment and pretreatment) in lung function.
MCC homogeneity
As reported previously,(4) average rate of whole lung
MCC through 60 minutes was enhanced after 1 month of
ivacaftor therapy (Fig. 5). Mean MCC through 60 minutes
increased from 12% to 24% ( p = 0.005, SD of the d = 12)
(Table 2). There was no difference in C/P (Table 1) between
pretherapy and posttherapy that might have influenced the
difference seen in clearance. Furthermore, there was no
correlation, either pretreatment or posttreatment, between C/
P and C60 in these CF patients (r = 0.05 and 0.23, respec-
tively). MCC was also not correlated with FEV1 across all
sites for pretreatment and posttreatment.
The mean pretreatment MCC of 12 – 10% (SD) at 60
minutes was used to determine the threshold of 30% clear-
ance (i.e., 2.5 X mean MCC) for our fast clearing pixels
(FR) and 5% clearance (mean MCC/2.5) for our slow
clearing pixels (SLR). We found that the fraction of noncold
pixels clearing >30% at 60 minutes (FR) increased from
0.13 to 0.32 ( p = 0.002, SD of the d = 0.18). Figure 6a il-
lustrates the individual subject changes in FR coded by site.
Furthermore, there were fewer slow clearing pixels (<5%
threshold) as SLR decreased significantly from 0.54 to 0.37
( p = 0.008, SD of the d = 0.20) (Fig. 6b). Both FR and SLR
were significantly correlated with MCC through 60 minutes
(r = 0.80 and -0.64, respectively, p < 0.001). Similarly, the
changes in FR and SLR with treatment (i.e., posttreatment
and pretreatment) were significantly correlated with the
treatment change in MCC [r = 0.82 ( p < 0.001) and -0.70
( p < 0.01), respectively].
For comparison to deposition homogeneity, there was no
correlation between either SR or NR hot versus FR in these
patients [r < abs (0.27) for any comparison, pretreatment or
posttreatment]. Only SLR was significantly correlated with
FEV1 percent of predicted (r = -0.48, p = 0.01) across all
patients and study visits. Changes in SLR or FR with
treatment were not significantly correlated with either pre-
treatment or changes (posttreatment and pretreatment) in
FEV1. Figure 6c provides a mean distribution of FR for all
possible thresholds in increments of 5% from 5% to 90% for
pretreatment and posttreatment. There is a general increase
in FR at all thresholds, indicating that all clearable (i.e., non
cold) pixels were affected by the treatment. This is likely the
benefit of using a systemic, rather than inhaled, therapy to
stimulate MCC.
Discussion
Using pixel analysis of gamma scintigraphy images to
assess the homogeneity of radiolabeled particle deposition
and clearance, we have shown that 1 month of treatment
with the CFTR potentiator, ivacaftor, in CF patients with at
least one copy of the G551D mutation improved homoge-
neity of aerosol particle deposition, more than double the
number of pixels that exhibited fast clearance, and signifi-
cantly reduced the number of slow clearing pixels. These
data further support the effectiveness of ivacaftor in these
patients. The improvement in the homogeneity of deposition
and clearance endpoints was not correlated with either
baseline or improved lung function (FEV1), suggesting that
these analyses may provide unique biomarkers of efficacy
that reflect improved ventilation and MCC with therapy in
CF. It remains to be determined if these analyses can be
shown to be more sensitive than typical lung function end-
points in studies where changes in the latter may be unde-
tectable.
The change in deposition homogeneity, in terms of both
decreased cold and hot pixels, was significant with treat-
ment, despite there being no effect on the traditional re-
gional deposition indices of C/P ratio and skew. As with our
previous comparison between healthy and CF subjects,(3)
these deposition homogeneity indices, especially NR of cold
pixels, were more sensitive than either C/P or skew. The
decrease in cold pixels following ivacaftor likely reflects an
improvement in regional ventilation, allowing increased
penetration of inhaled aerosols to previously poorly venti-
lated lung. Consistent with the improved ventilation, the
decrease in hot pixels following therapy likely reflects a
posttreatment decrease in sites of airway mucus obstruction
where particles tend to deposit by inertial impaction.
While it may be surprising that nC/P was also not decreased
following therapy, it is important to note that the C and P
regions only differ by the presence of the largest bronchial air-
ways of the lung in the C region, that is, both regions have
intermediate, small, and alveolated airways. The decrease in
deposition associated with excess airway mucus following
treatment could be similarly associated with both C and P
regions resulting in no observed change in nC/P.
The pixel analysis of clearance kinetics we describe in this
study is the first attempt to assess MCC on such a refined
scale, that is, not using large ROIs. Such an analysis requires
accurate alignment of images over time. In our case, we ac-
complished this by using the two fixed Americium markers
placed over each subject’s spine and simultaneously collecting
dual isotope (99mTc and 241Am) images for use in subsequent
analysis. We chose clearance through 60 minutes (comparison
of 60-minute image to deposition image) because the orig-
inal study design for this multisite study included controlled
coughing between the 60- and final 90-minute retention
FIG. 5. Mean fraction (–SD) of particles cleared from the
whole lung normalized to initial deposition for before versus
after 1-month ivacaftor therapy. SD, standard deviation.
measures. Thus, we wanted to restrict our analysis to MCC
at the latest point of measurement without cough.
While the definition of fast and slow clearing pixels as
2.5X and 1/2.5, respectively, of the mean baseline clearance
value seems somewhat arbitrary, subsequent analysis sug-
gested that this definition produced near maximal differ-
ences in FR between pretreatment and posttreatment
(Fig. 6c). Future analyses using software developed to better
assess rates of clearance from pixels over time, as opposed
to at a given time point of 60 minutes, may allow for more
sensitive and detailed mapping of pixel clearance kinetics.
We also measured the aggregate clearance from a given
pixel, or more likely in our case, a small cluster of pixels. A
group of pixels must have activity leaving faster than that
entering to be defined as fast clearing pixels (at least above
our threshold definitions). The opposite is true for slow
clearing pixels. It should be noted, however, that this effect
occurs to a much greater degree in regional analysis of clear-
ance using traditional large ROIs [e.g., in our case, a typical C
region with pixel dimensions of 25 · 50 (or 80 · 160 mm)
where activity is moving in/accumulating from the P region,
while moving through and out of the lung], again supporting
our assertion that our new approach provides better resolu-
tion on homogeneity of regional clearance than the tradi-
tional ROI approach.
In fact, we were able to show a significant increase in the
fraction of lung with rapid MCC after 1 month of ivacaftor
treatment. There was a 2.5-fold increase in fast clearing
pixels after ivacaftor (FR = 13 vs. 32%) and a 1/3 reduction
of slow clearing pixels (SLR = 54 vs. 37%). This appears to
account for all of the 2-fold increase in whole lung clearance
at 60 minutes (Fig. 5) between pretreatment and posttreat-
ment. The fact that we found an increase in fast clearing
areas, despite having a reduction in hot deposition pixels,
Table 2. Clearance Homogeneity by Site and for All Subjects
UNC pre (n = 7) UNC post JHU pre (n = 6) JHU post All pre (n = 13) All post
MCC (%) 12 (9) 27 (15) 12 (11) 20 (5) 12 (10) 24* (12)
FR 0.14 (0.13) 0.35 (0.19) 0.12 (0.14) 0.29 (0.10) 0.13 (0.13) 0.32* (0.15)
SLR 0.56 (0.10) 0.39 (0.23) 0.53 (0.19) 0.34 (0.12) 0.54 (0.14) 0.37^ (0.18)
Mean (SD) values displayed in table. p < 0.01* or 0.05^ compared to pre.
FR, fast clearing regions; MCC, mucociliary clearance; SLR, slow clearing regions.
FIG. 6. (a) Change in fraction of FR for pretreatment versus posttreat-
ment. Solid lines are from subjects recruited by UNC and dashed lines from
JHU. (b) Change in fraction of SLR for pretreatment versus posttreatment.
Solid lines are from subjects recruited by UNC and dashed lines from JHU.
(c) Histogram of mean FR for all subjects with clearance (%) thresholds at
60 minutes ranging from 5% to 90%. FR, fast clearing ratio; SLR, slow clearing
ratio.
illustrates that lower deposition areas were also sped up. In
other words, the enhanced MCC associated with ivacaftor
treatment was not merely a speeding of regions that were
already fast before treatment, but rather a result of both a
reduction of slow clearing regions as well as an increase in
the area of normal clearing regions. This is an important
finding that likely reflects the ability of a systemic agent to
reach poorly ventilating lung units through the pulmonary
circulation, and dramatically improve lung function in these
CF patients.
As with any new analytical tool, our pixel analysis ap-
proach has its limitations and potential for improvement.
While we use numbers/fraction of pixels to define hot versus
cold and fast versus slow regions, we acknowledge that we
do not have the ability to resolve airway volumes at the
pixel level (e.g., 3 · 3 mm) with the current data, but more
like a small cluster of pixels as defined in the methods.
Higher resolution/less sensitive collimators could be used in
the future to improve pixel resolution.
Our approach may also be developed further to compare
the deposition and retention scintigrams to CT lung scans in
the same individual, that is, to obtain anatomical informa-
tion associated with the hot/cold spots of deposition and
fast/slow regions of clearance. Such comparisons, to be
useful, would require accurate coregistration of images, that
is, use of fiducial markers to align images. It should be noted
that improvements in both resolution and anatomical defi-
nition require significantly higher radiation exposure to
patients, requiring appropriate risk-to-benefit assessment for
a given study.
Despite these limitations we believe our approach pro-
vides a significant improvement over the use of large ROIs
to assess regional deposition and clearance (e.g., from C and
P regions that are somewhat arbitrarily defined to corre-
spond to areas of the lung with and without large bronchial
airways). In addition, the thresholds used in this analysis for
determining FR were selected to detect changes in CF lung
with ivacaftor intervention and may need to be adjusted for
different therapies and lung conditions.
Conclusion
We have shown that pixel analyses of particle deposition
and clearance following ivacaftor treatment in CF patients
with G551D-CFTR improves (1) homogeneity of particle de-
position, likely due to improved regional ventilation, and (2)
clearance from a greater fraction of the whole lung. These
findings enhance our understanding of the mechanism of ac-
tion for ivacaftor. The image analysis methods used in this
study may supplement traditional methods for assessing effi-
cacy and mechanisms associated with therapeutic intervention
in patients with airways disease.
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